Benvinguts
El grup BCLC de l’Hospital Clínic de Barcelona és un equip multidiciplinar que engloba totes les especialitats mèdiques rellevants dedicades a la pràctica clínica, recerca i educació en el camp del càncer de fetge. Combina diagnòstic i teràpies d’última generació amb el desenvolupament de diferents projectes de recerca per a avaluar noves opcions de tractament. Aquests inclouen estudis en laboratori amb cultius cel.lulars o models animals i assaigs clínics en pacients amb càncer de fetge.
Últimes notícies
Publicacions recents
JOURNAL ARTICLE
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH. Grøndal SM, Tutusaus A, Boix L, Reig M, Blø M, Hodneland L, Gausdal G, Jackson A, Garcia de Frutos P, Lorens JB, Morales A, Marí M. Front Immunol. 2024;10.3389/fimmu.2024.1400553.
Pubmed abstract
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH. Grøndal SM, Tutusaus A, Boix L, Reig M, Blø M, Hodneland L, Gausdal G, Jackson A, Garcia de Frutos P, Lorens JB, Morales A, Marí M. Front Immunol. 2024;10.3389/fimmu.2024.1400553.
Pubmed abstract
JOURNAL ARTICLE
Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study. Ríos J, Sapena V, Mariño Z, Bruix J, Forns X, Morros R, Reig M, Torres F, Pontes C. Drugs Real World Outcomes. 2024;10.1007/s40801-024-00437-y.
Pubmed abstract
Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study. Ríos J, Sapena V, Mariño Z, Bruix J, Forns X, Morros R, Reig M, Torres F, Pontes C. Drugs Real World Outcomes. 2024;10.1007/s40801-024-00437-y.
Pubmed abstract
JOURNAL ARTICLE
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Van Dao T, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL.J Hepatol. 2024;10.1016/j.jhep.2024.07.017
Pubmed abstract
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Van Dao T, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL.J Hepatol. 2024;10.1016/j.jhep.2024.07.017
Pubmed abstract
JOURNAL ARTICLE
Rare primary liver cancers: An EASL position paper. Wege H, Campani C, de Kleine R, Meyer T, Nault JC, Pawlik TM, Reig M, Ricke J, Sempoux C, Torzilli G, Zucman-Rossi J.J Hepatol. 2024;10.1016/j.jhep.2024.06.004.
Pubmed abstract
Rare primary liver cancers: An EASL position paper. Wege H, Campani C, de Kleine R, Meyer T, Nault JC, Pawlik TM, Reig M, Ricke J, Sempoux C, Torzilli G, Zucman-Rossi J.J Hepatol. 2024;10.1016/j.jhep.2024.06.004.
Pubmed abstract
JOURNAL ARTICLE
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death. Cabibbo G, Celsa C, Battaglia S, Enea M, Di Maria G, Grova A, Ciccia R, Manfredi GF, Iavarone M, Vogel A, Singal AG, Reig M, Pinato DJ, Cammà C.Clin Cancer Res. 2024;10.1158/1078-0432.CCR-24-2582.
Pubmed abstract
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death. Cabibbo G, Celsa C, Battaglia S, Enea M, Di Maria G, Grova A, Ciccia R, Manfredi GF, Iavarone M, Vogel A, Singal AG, Reig M, Pinato DJ, Cammà C.Clin Cancer Res. 2024;10.1158/1078-0432.CCR-24-2582.
Pubmed abstract
JOURNAL ARTICLE
Utilizing a domain-specific large language model for LI-RADS v2018 categorization of free-text MRI reports: a feasibility study. Matute-González M, Darnell A, Comas-Cufí M, Pazó J, Soler A, Saborido B, Mauro E, Turnes J, Forner A, Reig M, Rimola J.Insights Imaging. 2024;10.1186/s13244-024-01850-1.
Pubmed abstract
Utilizing a domain-specific large language model for LI-RADS v2018 categorization of free-text MRI reports: a feasibility study. Matute-González M, Darnell A, Comas-Cufí M, Pazó J, Soler A, Saborido B, Mauro E, Turnes J, Forner A, Reig M, Rimola J.Insights Imaging. 2024;10.1186/s13244-024-01850-1.
Pubmed abstract
JOURNAL ARTICLE
Genome-wide DNA methylation markers associated with metabolic liver cancer. Antwi SO, Siaw ADJ, Armasu SM, Frank JA, Yan IK, Ahmed FY, Izquierdo-Sanchez L, Boix L, Rojasti A, Banales JM, Reig M, Stål P, Romero Gómez M, Wangensteen KJ, Singal AG, Roberts LR, Patel T. medRxiv . 2024;10.1101/2024.11.15.24317378.
Pubmed abstract
Genome-wide DNA methylation markers associated with metabolic liver cancer. Antwi SO, Siaw ADJ, Armasu SM, Frank JA, Yan IK, Ahmed FY, Izquierdo-Sanchez L, Boix L, Rojasti A, Banales JM, Reig M, Stål P, Romero Gómez M, Wangensteen KJ, Singal AG, Roberts LR, Patel T. medRxiv . 2024;10.1101/2024.11.15.24317378.
Pubmed abstract
JOURNAL ARTICLE
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martín-Liberal J, Joerger M, Alonso G, Goebeler ME, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz ME, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo JJ, Koster KL, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt AM, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle PR, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll FJ, Wild P, Chun FKH, Reis H, Lloyd P, Machacek M, Gajewski TF, Fridman WH, Eggermont AMM, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, da Silva A, Lichtenegger FS, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Nature 2024;10.1038/s41586-024-08305-z
Pubmed abstract
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martín-Liberal J, Joerger M, Alonso G, Goebeler ME, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz ME, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo JJ, Koster KL, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt AM, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle PR, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll FJ, Wild P, Chun FKH, Reis H, Lloyd P, Machacek M, Gajewski TF, Fridman WH, Eggermont AMM, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, da Silva A, Lichtenegger FS, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Nature 2024;10.1038/s41586-024-08305-z
Pubmed abstract
JOURNAL ARTICLE
Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection. Fuster-Anglada, C., Mauro, E., Ferrer-Fàbrega, J., Caballol, B., Sanduzzi-Zamparelli, M., Bruix, J., Fuster, J., Reig, M., Díaz, A., & Forner, A. Journal of hepatology 2024;doi:10.1016/j.jhep.2024.06.018
Pubmed abstract
Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection. Fuster-Anglada, C., Mauro, E., Ferrer-Fàbrega, J., Caballol, B., Sanduzzi-Zamparelli, M., Bruix, J., Fuster, J., Reig, M., Díaz, A., & Forner, A. Journal of hepatology 2024;doi:10.1016/j.jhep.2024.06.018
Pubmed abstract
JOURNAL ARTICLE
Systemic therapies in hepatocellular carcinoma: A revolution? Fortuny M, Sanduzzi-Zamparelli M, Reig M. S
United European Gastroenterol J. 2024; 10.1002/ueg2.12510 ;
Pubmed abstract
Systemic therapies in hepatocellular carcinoma: A revolution? Fortuny M, Sanduzzi-Zamparelli M, Reig M. S
United European Gastroenterol J. 2024; 10.1002/ueg2.12510 ;
Pubmed abstract
JOURNAL ARTICLE
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice. Cabibbo, G., Celsa, C., Rimassa, L., Torres, F., Rimola, J., Kloeckner, R., Bruix, J., Cammà, C., & Reig, M. (2024).
Journal of hepatology 2024 10.1016/j.jhep.2024.01.018 ;
Pubmed abstract
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice. Cabibbo, G., Celsa, C., Rimassa, L., Torres, F., Rimola, J., Kloeckner, R., Bruix, J., Cammà, C., & Reig, M. (2024).
Journal of hepatology 2024 10.1016/j.jhep.2024.01.018 ;
Pubmed abstract
JOURNAL ARTICLE
Clinical presentation, diagnosis and staging of cholangiocarcinoma
Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A
Liver International 2019;10.1111/liv.14086
Pubmed abstract
Clinical presentation, diagnosis and staging of cholangiocarcinoma
Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A
Liver International 2019;10.1111/liv.14086
Pubmed abstract
JOURNAL ARTICLE
Diagnosis of Hepatic Nodules in Patients at Risk for Hepatocellular Carcinoma: LI-RADS Probability Versus Certainty
Bruix J, Ayuso C Gastroenterology 2019;10.1053/j.gastro.2019.02.008
Pubmed abstract
Diagnosis of Hepatic Nodules in Patients at Risk for Hepatocellular Carcinoma: LI-RADS Probability Versus Certainty
Bruix J, Ayuso C Gastroenterology 2019;10.1053/j.gastro.2019.02.008
Pubmed abstract
JOURNAL ARTICLE
Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma
Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, Bruix J
Gastroenterology 2019;10.1053/j.gastro.2019.01.261
Pubmed abstract
Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma
Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, Bruix J
Gastroenterology 2019;10.1053/j.gastro.2019.01.261
Pubmed abstract
JOURNAL ARTICLE
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib
Díaz-González Á, Sanduzzi-Zamparelli M, Sapena V, Torres F, LLarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M
Aliment Pharmacol Ther 2019;49:482-491
Pubmed abstract
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib
Díaz-González Á, Sanduzzi-Zamparelli M, Sapena V, Torres F, LLarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M
Aliment Pharmacol Ther 2019;49:482-491
Pubmed abstract
JOURNAL ARTICLE
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules
Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, de Lope CR, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M
J Hepatology 2019;10.1016/j.jhep.2019.01.005
Pubmed abstract
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules
Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, de Lope CR, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M
J Hepatology 2019;10.1016/j.jhep.2019.01.005
Pubmed abstract